Signatures of electrical activity have been identified in the brains of people with chronic pain. Although a small study, the discovery could one day lead to more effective treatments. Chronic pain, which lasts longer than 3 months, affects more than 30 per cent of the world's population, with existing therapies often having limited effectiveness. To help in the development of new treatments, Prasad Shirvalkar at the University of California, San Francisco, and his colleagues set out to better understand how the brain regulates pain. The team implanted electrodes and stimulators into the brains of four people with chronic pain as a result of a stroke or amputation.

AI is being used in many areas of human biology, including genetics, drug development, and medical imaging. One potential advancement that could be achieved with the use of AI in human biology is the ability to personalize medical treatments based on an individual's genetic makeup. By analyzing an individual's DNA, AI algorithms could identify specific genetic variations that may make them more or less responsive to certain drugs. This could lead to more effective treatments with fewer side effects. Another area where AI is being tested is in the early detection of diseases.

Andrew Watson is Vice President of AI and R & D at Healx. Prior to joining Healx he worked at the technology giant Dyson, where he was the founding member of the Machine Learning Research Department, leading the research and implementation of machine learning and artificial intelligence across a variety of global product categories. In his time as Director of Machine Learning at Dyson, Andrew also established a new research group, focused on the intersection between machine learning and cutting-edge biomedical research. Healx is an AI-powered, patient-inspired technology company, dedicated to helping rare disease patients around the world access life-improving therapies. There are 7,000 known rare diseases that affect 400 million people across the globe but only 5% of those conditions have approved treatments.

It's estimated that more than 6 million Americans -- and about 24 million people worldwide -- are living with the degenerative brain disease called Alzheimer's, a progressive mental deterioration that is the fifth leading cause of death in the United States among people who are 65 and older. The Alzheimer's Association and other sources report that medical experts estimate the number of people with this form of dementia more than doubling within the next three decades. That reality is leading to more research aimed at deepening knowledge about the causes and progression of the disease to help in developing effective treatments. One essential key to success is finding ways to more accurately detect the early indicators of the disease, for example, through neuroimaging -- generating images of the brain -- as well as ways to more clearly visualize its physiological signs. Among those taking on the challenge are researchers Teresa Wu, Yi Su and Jay Shah.

A new AI-based test that can predict the most effective treatment from images of routine cancer samples has been approved for use in the UK and EU, speeding up diagnosis and reducing the need for lab testing. Developed by Cambridge-based company Panakeia, the PANProfiler test analyses digital images of routinely collected breast tumour samples that are normally checked down a microscope by a trained pathologist to determine the presence of cancer. The usual next step would be to send a further sample for lab testing to identify the best treatment approach, with the results taking days or weeks and costing hundreds or even thousands of pounds depending on the test. However, the PANProfiler Breast test skips the need for testing by directly predicting whether the cancer contains ER or PR receptors, marking the patient out as a candidate for hormone therapy, or HER2, targeted by the drug Herceptin. All this happens from the original digital image in a matter of minutes, with accuracy comparable to lab testing, making the PANProfiler test far faster and significantly cheaper than existing tests.

Artificial intelligence (AI) has undoubtedly been a growing presence in the healthcare industry, shaving years and billions of pounds off drug development programmes, accurately predicting A&E influxes, and even detecting early signs of disease in patients years before it was thought possible. The field of neuroscience has been no exception to this wave of technological innovation, with exciting developments cropping up in recent months and years that could potentially revolutionise diagnoses, treatments, and outcomes for patients on a global scale. The term AI covers a field of computer science that is focused upon the simulation of human intelligence and computational processes. However, there are several subfields of AI technology currently being explored in neuroscience, including machine learning (ML) and deep learning (DL). AI covers all programming systems that can perform tasks which usually require human intelligence.

Enzolytics, Inc. (ENZC) is making a powerful move up the charts in recent days since a brief dip below the $0.10 mark. ENZC is a major league runner and powerhouse stock; over the past few months ENZC has seen a legendary run to recent highs of 0.958 per share as it completes the historic merger between BioClonetics and Enzolytics; the new biotech is getting noticed as its technology for producing fully human monoclonal antibodies is currently being employed to produce anti-SARS-CoV-2 (CoronaVirus) monoclonal antibodies for treating COVID-19. With each day of progression of the Coronavirus pandemic, the dire need for multiple active therapeutics becomes more evident. ENZC is a pioneer in using monoclonal antibodies for treating COVID-19. ENZC has partnered with Intel to publish a white paper titled, "Optimizing Empathetic A.I. to Cure Deadly Diseases," highlighting Intel's Artificial Intelligence Analytic tools and Enzolytic's innovative approach and groundbreaking contributions to create universal, durable, and broadly effective treatment targeting all virus variants.

We propose a new unified framework for causal inference when outcomes depend on how agents are linked in a social or economic network. Such network interference describes a large literature on treatment spillovers, social interactions, social learning, information diffusion, social capital formation, and more. Our approach works by first characterizing how an agent is linked in the network using the configuration of other agents and connections nearby as measured by path distance. The impact of a policy or treatment assignment is then learned by pooling outcome data across similarly configured agents. In the paper, we propose a new nonparametric modeling approach and consider two applications to causal inference. The first application is to testing policy irrelevance/no treatment effects. The second application is to estimating policy effects/treatment response. We conclude by evaluating the finite-sample properties of our estimation and inference procedures via simulation.

Globally, there is a huge unmet need for effective treatments for neurodegenerative diseases. The complexity of the molecular mechanisms underlying neuronal degeneration and the heterogeneity of the patient population present massive challenges to the development of early diagnostic tools and effective treatments for these diseases. Machine learning, a subfield of artificial intelligence, is enabling scientists, clinicians and patients to address some of these challenges. In this Review, we discuss how machine learning can aid early diagnosis and interpretation of medical images as well as the discovery and development of new therapies. A unifying theme of the different applications of machine learning is the integration of multiple high-dimensional sources of data, which all provide a different view on disease, and the automated derivation of actionable insights. In this Review, the authors describe the latest developments in the use of machine learning to interrogate neurodegenerative disease-related datasets. They discuss applications of machine learning to diagnosis, prognosis and therapeutic development, and the challenges involved in analysing health-care data.

Question: You lead the "Scientific Data Management" research group at TIB – Leibniz Information Centre for Science and Technology. You focus your research on how big data technologies can be used in the health sector to improve health care. What exactly are you researching? The amount of available big data has grown drastically in the last decade, and it is expected a faster growth rate in the coming years. Specifically, in the biomedical domain, there are a wide variety of methods, e.g.